NICE recommends Keytruda and chemo as first-line esophageal cancer drug
The National Institute for Health and Care Excellence (NICE) has recommended Keytruda (pembrolizumab) in an indication for which it won UK approval just two months ago.
Merck & Co’s (NYSE: MRK) immuno-oncology blockbuster has been recommended alongside platinum- and fluoropyrimidine-based chemotherapy for untreated, locally-advanced unresectable or metastatic carcinoma of the esophagus or HER-2 negative gastro-esophageal junction adenocarcinoma in adults whose tumors express PD-L1 with a combined positive score (CPS) of 10 or more.
"I am proud that MSD has been able to contribute to filling this void"The combination was shown to extend the lives of certain patients newly diagnosed with late-stage esophageal cancer in a Phase III trial – reducing the risk of growth and spread of patients’ tumors compared with standard of care chemotherapy, with a manageable safety profile.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze